Venerito Marino, Goni Elisabetta, Malfertheiner Peter
a Department of Gastroenterology, Hepatology and Infectious Diseases , Otto-von-Guericke University Hospital , Magdeburg , Germany.
Expert Rev Gastroenterol Hepatol. 2016;10(4):497-503. doi: 10.1586/17474124.2016.1126507. Epub 2016 Jan 5.
Helicobacter pylori gastritis is the most frequent infectious disease in the gastrointestinal tract. Clinical sequelae of the infection including peptic ulcer disease, sporadic gastric cancer (GC) and primary B-cell gastric lymphoma (MALT-lymphoma) may develop in up to 20% of the infected individuals. The H. pylori screen-and-treat strategy is addressed to members of communities with high GC incidence, and first-degree relatives of GC patients. For primary GC prevention, H. pylori screen-and-treat is most effective in patients without precancerous conditions. In populations at moderate risk, strategies for GC prevention need to be explored. A special clinical scenario for primary and secondary prevention of H. pylori related benign complications are patients on non-steroidal anti-inflammatory drugs and low-dose aspirin. Vaccination represents another option for eliminating H. pylori infection in the population and a new H. pylori vaccine has shown promising results. However, long-term effects with the use of vaccine are not available.
幽门螺杆菌胃炎是胃肠道最常见的传染病。该感染的临床后遗症包括消化性溃疡病、散发性胃癌（GC）和原发性B细胞胃淋巴瘤（MALT淋巴瘤），在高达20%的受感染个体中可能会出现。幽门螺杆菌筛查和治疗策略适用于GC发病率高的社区成员以及GC患者的一级亲属。对于原发性GC预防，幽门螺杆菌筛查和治疗在没有癌前病变的患者中最有效。在中度风险人群中，需要探索GC预防策略。对于幽门螺杆菌相关良性并发症的一级和二级预防，一种特殊的临床情况是使用非甾体抗炎药和低剂量阿司匹林的患者。疫苗接种是消除人群中幽门螺杆菌感染的另一种选择，一种新的幽门螺杆菌疫苗已显示出有希望的结果。然而，使用疫苗的长期效果尚不可知。
